http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Effect of Indium on the Microstructures and Mechanical Properties of Dental Gold Alloys
Jung, H.Y.,Lee, S.H.,Doh, Jung Mann,Yoon, Jin Kook,Lim, H.N. Trans Tech Publications, Ltd. 2006 Materials science forum Vol.510 No.-
<P>The effect of indium on the microstructures and mechanical properties of a Au-Pt-Cu alloy was investigated. The Au-Pt-Cu-xIn alloys heat-treated at 550°C for 30 min revealed a maximum hardness value of 207 HV, irrespective of the heat temperature and In contents. Also, the hardness of the Au-Pt-Cu-xIn alloys (x = 0.5, 1.0, 1.5, 2.0) aged at 550 °C rapidly increased with increasing aging time, and it reached an almost constant value after 30 min. The hardness of the Au- Pt-Cu-xIn alloys aged at 550°C for 30 min increased with increasing In content until 1.5wt%, but it slightly decreased with more increasing In content. Also, a variation of the tensile strength of the alloys with In contents showed a similar trend of hardness change with In contents. Analysis of EDS and TEM revealed that the microstructure of Au-Pt-Cu-xIn alloys is composed of solid solution with fcc structure and intermetallic InPt3 precipitate with L12 structure. Based on this investigation, it can be concluded that an increase in hardness of Au-Pt-Cu-xIn alloys is ascribed to a complex effect of the precipitation hardening of InPt3 and the grain size refinement.</P>
( Eric Lawitz ),( Michael Manns ),( Marc Bourliere ),( Sooji Lee ),( Nelson Cheinquer ),( Luisa Stamm ),( Robert H. Hyland ),( Liyun Ni ),( Hadas Dvory-sobol ),( Diana Brainard ),( Mani Subramanian ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: The pangenotypic fixed-dose combination (FDC) of sofosbuvir (SOF), a HCV NS5B inhibitor, velpatasvir (VEL), a HCV NS5A inhibitor, and voxilaprevir (VOX), a HCV NS3/4A protease inhibitor, is an salvage regimen for direct acting antiviral (DAA)-experienced patients based on the safety and efficacy demonstrated in Phase 2 and Phase 3 trials in this population. Methods: This was a retrospective analysis of data from 454 NS5A inhibitor-experienced patients treated with SOF/VEL FDC+VOX or SOF/VEL/VOX FDC in the Phase 2 and Phase 3 trials. Efficacy was assessed by SVR12 and relapse rates. Safety was assessed by treatment-emergent adverse events (AEs) and laboratory abnormalities. Results: Of 454 NS5A inhibitor-experienced patients treated, 77% were male, 41% had compensated cirrhosis, 86% had NS5A and NS3 baseline resistance-associated substitutions (RASs), 74% had genotype 1 HCV infection. Most patients (53%) had previously been exposed to NS5A inhibitor+NS5B inhibitor, with 39% exposed to NS5A inhibitor+NS3/4A protease inhibitor±NS5B inhibitor and 8% exposed to NS5A inhibitor±another DAA. Overall, the SVR12 rate was 97% with a relapse rate of 2%. The SVR12 rate in patients with compensated cirrhosis was 95% and in patients with baseline RASs was 97%. The SVR12 rates by prior regimen were: NS5A inhibitor+NS5B inhibitor 95%; NS5A inhibitor+NS3/4A protease inhibitor±NS5B inhibitor 99%; and NS5A inhibitor±another DAA 100%. Treatment-emergent RASs were uncommon, present in 3 of 10 patients who relapsed. Only 1 patient (0.2%) discontinued treatment due to an AE. No serious adverse events attributed to study medication were reported. Conclusions: Results in over 450 NS5A inhibitor-experienced patients enrolled in Phase 2 or Phase 3 trials demonstrate that the 3-DAA combination of SOF, VEL and VOX for 12 weeks is a safe, well tolerated and effective treatment for patients who previously failed an NS5A inhibitor-containing regimen, irrespective of the other drugs in the prior treatment.
Four Extended-Reach TDM PONs Sharing a Bidirectional Hybrid CWDM Amplifier
Iannone, P.P.,Lee, H.H.,Reichmann, K.C.,Zhou, X.,Du, M.,Palsdottir, B.,Feder, K.,Westbrook, P.,Brar, K.,Mann, J.,Spiekman, L. IEEE 2008 Journal of lightwave technology Vol.26 No.1
<P>We demonstrate four conventional TDM PONs with symmetric 2.5-Gb/s line rate and extended reach, sharing a common infrastructure. A hybrid SOA-Raman amplifier provides 150-nm bidirectional gain over the PONs' downstream and upstream CWDM wavelength plan.</P>
Park, K.,Kim, Y.I.,Shin, K.O.,Seo, H.S.,Kim, J.Y.,Mann, T.,Oda, Y.,Lee, Y.M.,Holleran, W.M.,Elias, P.M.,Uchida, Y. Butterworths ; Elsevier Science Ltd 2014 The Journal of nutritional biochemistry Vol.25 No.7
We recently discovered that a signaling lipid, sphingosine-1-phosphate (S1P), generated by sphingosine kinase 1, regulates a major epidermal antimicrobial peptide's [cathelicidin antimicrobial peptide (CAMP)] expression via an NF-κB→C/EBPα-dependent pathway, independent of vitamin D receptor (VDR) in epithelial cells. Activation of estrogen receptors (ERs) by either estrogens or phytoestrogens also is known to stimulate S1P production, but it is unknown whether ER activation increases CAMP production. We investigated whether a phytoestrogen, genistein, simulates CAMP expression in keratinocytes, a model of epithelial cells, by either a S1P-dependent mechanism(s) or the alternate VDR-regulated pathway. Exogenous genistein, as well as an ER-β ligand, WAY-200070, increased CAMP mRNA and protein expression in cultured human keratinocytes, while ER-β antagonist, ICI182780, attenuated the expected genistein- and WAY-200070-induced increase in CAMP mRNA/protein expression. Genistein treatment increased acidic and alkaline ceramidase expression and cellular S1P levels in parallel with increased S1P lyase inhibition, accounting for increased CAMP production. In contrast, siRNA against VDR did not alter genistein-mediated up-regulation of CAMP. Taken together, genistein induces CAMP production via an ER-β→S1P→NF-κB→C/EBPα- rather than a VDR-dependent mechanism, illuminating a new role for estrogens in the regulation of epithelial innate immunity and pointing to potential additional benefits of dietary genistein in enhancing cutaneous antimicrobial defense.
Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones
Chenine, Agnes-Laurence,Merbah, Melanie,Wieczorek, Lindsay,Molnar, Sebastian,Mann, Brendan,Lee, Jenica,O’Sullivan, Anne-Marie,Bose, Meera,Sanders-Buell, Eric,Kijak, Gustavo H.,Herrera, Carolina,McLind Wolters Kluwer Health, Inc. All rights reserved. 2018 Journal of acquired immune deficiency syndromes Vol.78 No.3
<P>Conclusions: This novel panel of CRFOl_AE reporter IMC is useful for assessing vaccine-induced neutralizing antibodies in multiple assays, including those using primary cell targets. The significant differences in TZM-bl and A3R5 neutralization sensitivity, as well as the poor association when using polyclonal sera indicates the need for caution in choosing one specific platform.</P>
오보영,김정희,공용우,제갈승,김혜영,이미연,황경화,고연자,이제만,고종명,김용희,Oh, Bo-Young,Kim, Jung-Hee,Gong, Young-Woo,JeGal, Seung,Kim, Hye-Yeung,Lee, Mi-Yeon,Hwang, Kyoung-Wha,Koh, Yeon-Ja,Lee, Jae-Mann,Go, Jong-Myoung,Kim, Yong-H 한국미생물학회 2007 미생물학회지 Vol.43 No.4
2006년도 인천지역 해양환경에서 분리된 Vibrio vulnificus에 대한 생화학적, 분자생물학적 특성 및 항생제 감수성 결과를 알아보았다. 본 실험에 사용된 균주는 총 233주로 해수, 갯벌, 어패류, 수족관수에서 분리되었다. API 20E kit 실험 결과 15개 profile로 분류되었으며, 모든 균주가 ONPG와 Amygdalin 양성이었다. 209주를 대상으로 vvhA와 viuB 유전자 부위에 대해 PCR 실험결과 vvhA는 206주(98.6%) 양성, viuB는 110주(52.6%)가 양성이었으며, 특히 viuB 유전자부위에 대한 PCR 결과는 해수, 어패류, 갯벌에서 분리한 균주의 48%, 48.5%, 61.1%가 양성인 것으로 나타났다. 시험균주 175주에 대해 항생제 감수성 실험 결과 Imipenem (100.0%), Sulfamethoxazole/trimethoprim (98.9%), Tetracycline, Ciprofloxacin (98.3%), Ampicillin/sulbactam (97.1%), Chloramphenicol (96.6%), Cefepime (94.9%), Ceftriaxone (94.8%)이 감수성을 나타내었고, 항생제 하나 또는 그 이상의 약제에 대해 내성을 나타낸 것은 56주(32%)로 해수 28주(31.5%), 갯벌 21주(34.4%), 어패류 7주(29.2%)였다. V. vulnificus 233주에 대해 PFGE를 실시하여 dendrogram으로 분석한 결과 90%이상의 상동성 기준으로 126개의 유형으로 분리되었고, 58%이상의 상동성을 기준으로 13개의 cluster로 분류되었다. Cluster I는 104주(44.6%)로 가장 많은 균주들이 분포하였고 채취시기 대부분 I에 가장 많은 균주들이 분포하였으나 10월과 6월에 채취한 검체는 J에 16주(69.6%)와 13주(36.1%)로 가장 많은 균주들이 분포하였다. 7월에 채취한 검체에서 분리된 균주는 9개의 cluster에 속하였고 8월은 8개, 6월은 7개, 9월은 6개, 10월은 5개, 5월은 3개, 3월은 1개를 나타냈다. We performed the biochemical characteristics, molecular epidemiologocal analysis, and drug susceptibility test on V. vulnificus isolated from environmental sources in Incheon. For this study, 233 strains were isolated from seawater, sediment, shellfish. V. vulnificus isolates were divided into 15 biochemical groups, which were positive for ONPG and Amygdalin test. Among the 209 strains, 206 (98.6%) strains and 110 (52.6%) strains revealed positive for vvhA and viuB gene, and the viuB gene detection rates of V. vulnificus from seawater, shellfish and sediment were 48%, 48.5% and 61.6%, respectively. From disc diffusion test on 175 isolates, most of strains were sensitive to Imipenem (100.0%), Sulfamethoxazole/trimethoprim (98.9%), Tetracycline, Ciprofloxacin (98.3%), Ampicillin/sulbactam (97.1%), Ohloramphenicol (96.6%), Cefepime (94.9%) and Ceftriaxone (94.8%), multi-drug resistance rates was 31.5% of seawater, 34.4% of sediment and 29.2% of shellfish. PFGE was performed on 233 V. vulnificus isolates with the objective of investigating the extent of genetic diversity of these isolates in our region. We could find that at least 126 different PFGE patterns were generated according by 90% of similarity and 13 clusters by 58% of similarity. The major cluster was type I (44.6%) during the most of the year, and type J was frequent pattern in June and October. There were 9 distinct PFGE types in July, 8 types in August, 7 types in June, 6 types in September, 5 types in October 3 types in May and 1 type in March.